Castleview Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Castleview Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-59	Closed	-$42.2K	–	468
2024 Q4	$42.2K	Hold	59	–	–	0.02%	361
2024 Q3	$62K	Hold	59	–	–	0.04%	301
2024 Q2	$62K	Hold	59	–	–	0.04%	309
2024 Q1	$56.8K	Hold	59	–	–	0.03%	337
2023 Q4	$51.8K	Hold	59	–	–	0.04%	289
2023 Q3	$48.6K	Hold	59	–	–	0.04%	259
2023 Q2	$42.4K	Hold	59	–	–	0.04%	273
2023 Q1	$48.5K	Hold	59	–	–	0.04%	268
2022 Q4	$42.6K	Hold	59	–	–	0.04%	244
2022 Q3	$41K	Sell	59 -3,221	-98%	-$2.03M	0.04%	275
2022 Q2	$61.5K	Buy	3,280 +3,221	+5,459%	+$2.09M	0.05%	274
2022 Q1	$41K	Buy	+59	New	+$37.3K	0.03%	369
2021 Q2	$33K	Buy	+59	New	+$29.9K	0.01%	485

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Castleview Partners's REGN Position: Q1 2025 in Review

Castleview Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 59 shares — an estimated $42.2K sold.

Castleview Partners first reported a position in REGN in Q2 2021 and held it in 13 quarters. The position peaked at $62K in Q3 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Castleview Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Castleview Partners sold 59 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $42.2K.
Castleview Partners first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 13 quarters.
Castleview Partners's Regeneron Pharmaceuticals position peaked at $62K in Q3 2024.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Castleview Partners's 13F filing for Q1 2025, filed 22 Apr 2025.